This Mentored Clinical Scientist Development Award (MCSDA) application addresses the pathophysiology of neuropathic pain. Nerve injury-induced neuropathic pain is usually accompanied by mechanical allodynia and thermal hyperalgesia, which result in depression, anxiety and a marked decrease in quality of life. Analgesics such as non-steroidal anti-inflammatory drugs and opiates are relatively ineffective in treating neuropathic pain, a fact that reflects our poor understanding of this phenomenon. Several drugs with some effectiveness in reducing neuropathic pain also significantly modulate intracellular calcium levels in sensory pathway cells. Targeting intracellular calcium mechanisms more directly may thus provide novel therapeutic options in neuropathic pain. Intracellular calcium regulatory mechanisms are often uniquely sculpted to serve cell-specific functions, yet surprisingly little is known about intracellular calcium homeostasis in sensory pathway cells of the dorsal root ganglion and spinal cord. The lack of approaches for preventing the development of neuropathic pain or to adequately control established neuropathic pain underscores the importance of understanding normal and injury-induced changes in the intracellular calcium regulation of sensory pathway cells. Our long-range goal is to develop effective strategies for preventing the development of and reversing established neuropathic pain. The objective of this application is to determine the contribution of altered intracellular Ca2+ regulatory mechanisms in sensory pathway cells and the development of neuropathic pain. The central hypothesis of the proposed research is that injury-induced changes in endoplasmic reticulum (ER) calcium sequestration and release mechanisms of dorsal root ganglion (DRG) cells and spinal cord dorsal horn sensory neurons underlie the development of nerve injury-induced neuropathic pain. We plan to test our hypothesis and accomplish the objective of this application by pursuing the following three specific aims. (1): To determine whether nerve injury-induced neuropathic pain alters intracellular calcium homeostasis in rat DRG neurons. (2): To determine whether nerve injury-induced neuropathic pain alters intracellular calcium homeostasis in rat spinal cord. (3): To determine whether thapsigargin, an ER calcium pump inhibitor, can reverse nerve injury-induced neuropathic pain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08DE014571-01A1
Application #
6571412
Study Section
NIDCR Special Grants Review Committee (DSR)
Program Officer
Hardwick, Kevin S
Project Start
2003-08-18
Project End
2008-05-31
Budget Start
2003-08-18
Budget End
2004-05-31
Support Year
1
Fiscal Year
2003
Total Cost
$103,295
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Podratz, Jewel L; Knight, Andrew M; Ta, Lauren E et al. (2011) Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 41:661-8
Ta, Lauren E; Bieber, Allan J; Carlton, Susan M et al. (2010) Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 6:15
Ta, Lauren E; Low, Philip A; Windebank, Anthony J (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 5:9
Ta, Lauren E; Espeset, Laura; Podratz, Jewel et al. (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992-1002